Integrity Applications, Scoring 75%, Has a Product Designed to Measure Glucose Without Needles

PRT_1056

INTEGRITY APPLICATIONS BUSINESS PERFORMANCE RATING: 75%

May, 2016

RATINGS (1-10)

ASSET PERFORMANCE FACTORS

BLUE SKY  10

This is a brand new market

COMPETITIVE AND INTELLECTUAL PROPERTY RISKS 2 Their are plenty of competitors trying to fill the need, many of whom are much larger PRODUCT MIX 1 They have only 1 product PRODUCT VALUE 10 Product is 97% accurate No pain to the patient measuring glucose level

EXTERNAL FACTORS

MARKETPLACE 10

The market is huge and growing

VALUATION 8

If it works it’s obviously undervalued

It only trades 150 shares a day

BUSINESS STRATEGY 10

Makes sense, to get the products sold in countries where they are allowed to sell it, combined with seeking approval in other countries

INTERNAL FACTORS

MANAGEMENT 10

Lots of experience

CAPITALIZATION AND FINANCIAL STRATEGY 10 They burn $3m-$4m and will increase 50% next year But they seem to have less than that in cash

MARKETING AND OPERATIONS 4

Marketing is tough for these and will be expensive for a small company G&A is high, at 8% of MV III. THE PRESENTATION General

Stuck to the presentation?          Y

Sophistication appropriate?        Y

The Handouts

Page numbers?                                                Y

Easy to read?                                     Y

Appropriate length?                       Y

Peer comparisons                            Y

Management Bios?                         Y

Price chart                                           Y

Projects and timelines

Timeline?                                            Y

Project pipeline?                              Y

Theralase, With a Credible Cure for Cancer, Has Dynamite Investment Potential and a Business Performance Rating of 78%

sharon   linkedin

THERALASE BUSINESS PERFORMANCE RATING: 78%

May, 2016

RATINGS (1-10)

ASSET PERFORMANCE FACTORS

BLUE SKY  9

These are both brand new products

There are laser therapeutics already in use by competitiors, though they claim their’s is superior I didn’t see any evidence in the presentation that their’s is superior to competitor’s The cancer drug is novel

COMPETITIVE AND INTELLECTUAL PROPERTY RISKS 8 They have patents on all of it As discussed above, there are competitors already in the laser therapeutics division To me, it sounds as though other companies could copy the approach to laser cancer treatment, since the mechanism by which their drug targets the cancer cell is well-described.  And I suspect a bright scientist can figure out how to make a cell with a light-activated mechanism

PRODUCT MIX 4

I like that one product has a currently cash-flow positive characteristic, which will support the clinical tests on the Laser cancer division I also like the diversification They have only 2 products, one of which is not ready for commercialization

PRODUCT VALUE 8

I didn’t see any proof that the laser therapeutic is superior to competitive products I did see great evidence that the cancer treatment is effective

 

EXTERNAL FACTORS

MARKETPLACE 10

The market is huge for both, and growing

PEER VALUATION 10

The stock is cheap given its potential

BUSINESS STRATEGY 10

Their strategy is sound, especially building a direct sales force

 

INTERNAL FACTORS

MANAGEMENT 9

Management knows it’s stuff

G&A is 6% of MV, which is high, but to be expected given the R&D and sales Insider ownership is a sizeable 7%

CAPITALIZATION AND FINANCIAL STRATEGY 4

Overhang is high, at 35% or so.  I’d prefer it under 25% Cash will last a year or less They will need to raise equity at low 0.30 cent prices

MARKETING AND OPERATIONS 6

They will need to build a direct sales force, which will be expensive

 

 

Integrity Applications, With a Novel Non-Invasive Way to Measure Diabetic Glucose, Scores 75%

Newport Polo 1507

INTEGRITY APPLICATIONS BUSINESS PERFORMANCE RATING: 75%

May, 2016 RATINGS (1-10)

ASSET PERFORMANCE FACTORS

BLUE SKY  10

This is a brand new market

COMPETITIVE AND INTELLECTUAL PROPERTY RISKS 2

Their are plenty of competitors trying to fill the need, many of whom are much larger

PRODUCT MIX 1 They have only 1 product

PRODUCT VALUE 10

Product is 97% accurate No pain to the patient measuing glucose level

EXTERNAL FACTORS

MARKETPLACE 10

The market is huge and growing

VALUATION 8

If it works it’s obviously undervalued

It only trades 150 shares a day

BUSINESS STRATEGY 10

Makes sense, to get the products sold in countries where they are allowed to sell it, combined with seeking approval in other countries

 

INTERNAL FACTORS

MANAGEMENT 10

Lots of experience

CAPITALIZATION AND FINANCIAL STRATEGY 10 They burn $3m-$4m and will increase 50% next year But they seem to have less than that in cash

MARKETING AND OPERATIONS 4

Marketing is tough for these and will be expensive for a small company G&A is high, at 8% of MV III. THE PRESENTATION General